Intra-Cellular Therapies Priced, Nasdaq: ITCI
Clinical-stage biotech developing treatments for neurological disorders.
Industry: Health Care
First Day Return: +10.9%
ITCI
Clinical-stage biotech developing treatments for neurological disorders.
| IPO Data | |
|---|---|
| IPO Date | 01/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $107 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2012 |
| Employees at IPO | 21 |
| Website www.intracellulartherapies.com | |
IPO News for Intra-Cellular Therapies
Intra-Cellular Therapies (ITCI) Performance
